PRAX — PRAXIS PRECISION MEDICINES I
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About PRAXIS PRECISION MEDICINES I (PRAX)
PRAXIS PRECISION MEDICINES I (PRAX) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $292M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in PRAX
How many top investors track PRAX
A small number of top investors own this.
PRAX Ownership Composition
How PRAXIS PRECISION MEDICINES I is held across tracked investor types, based on reported 13F positions.
- Hedge Funds91.2%
- Other8.8%
Tracked investors reporting PRAX
- Steve CohenDec 31, 2025Point72 Asset ManagementShares992.3KValue$292.5M% Portfolio0.33%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares76.5KValue$24.6M% Portfolio0.00%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares10.6KValue$3.4M% Portfolio0.00%
Recent activity
- Sold$0(-100.00%)May 15, 2026
- New$41KFeb 17, 2026
Frequently asked questions
- How many institutional investors hold PRAX?
- 3 tracked institutional investors disclosed a position in PRAX (PRAXIS PRECISION MEDICINES I) in their most recent 13F filing.
- Who is the largest institutional holder of PRAX?
- Steve Cohen, Point72 Asset Management, holds the largest disclosed position in PRAX, valued at $292M.
- Did institutional ownership of PRAX increase or decrease?
- Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 fully exited PRAX.
- Where does this PRAX ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.